·ù¸¶Æ¼½º°üÀý¿°ÀÌ µ¿¹ÝµÈ °íÀüÇü Ä«Æ÷½ÃÀ°Á¾ÀÇ ¿¡ÅäÆ÷»çÀ̵å Ä¡·á 1¿¹
A Case of Etoposide Therapy in a Patient Newly Diagnosed with Classic Kaposi¡¯s Sarcoma and Rheumatoid Arthritis

´ëÇѳ»°úÇÐȸÁö 2014³â 86±Ç 2È£ p.247 ~ p.252

ÃÖ³­¿µ(Choi Nan-Young) - ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹Ú½Â¾Æ(Park Seung-Ah) - ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÇѺ¸¶÷(Han Bo-Ram) - ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÈ£¿µ(Kim Ho-Young) - ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹Î¼ö±â(Min Soo-Kee) - ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
±èÈ¿Á¤(Kim Hyo-Jung) - ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Àå´ë¿µ(Zang Dae-Young) - ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç

Abstract

º» ÀúÀÚµéÀº ·ù¸¶Æ¼½º°üÀý¿°À» óÀ½ Áø´Ü¹Þ°í ¸é¿ªÀúÇÏÀÇ Áõ°Å°¡ ¾øÀ¸¸ç HHV-8 À½¼ºÀ̸ç Àü½Å»óÅ°¡ ÁÁÁö ¾ÊÀº °í·ÉÀÇ È¯ÀÚ¿¡¼­ Àü½Å ÇǺο¡ ¹ß»ýÇÑ 4º´±â °íÀüÇü Ä«Æ÷½ÃÀ°Á¾À» Áø´ÜÇÏ¿´°í Áö¼ÓÀûÀÎ Àú¿ë·® °æ±¸ ¿¡ÅäÆ÷»çÀÌµå ´Üµ¶¿ä¹ýÀ¸·Î ÁÁÀº ÀÓ»ó°æ°ú¸¦ ¾òÀº Áõ·Ê°¡ ÀÖ¾î º¸°íÇÏ´Â ¹Ù ÀÌ´Ù.
Kaposi¡¯s sarcoma typically occurs in immunocompromised patients, especially those with acquired immunodeficiency syndrome. Human herpesvirus 8 (HHV-8) and human immunodeficiency virus (HIV) may play important roles in the development of Kaposi¡¯s sarcoma. We report the case of a 75-year-old male who presented with progressive multiple purplish papules and nodules on the skin for 3 months. Social and past medical histories seemed incompatible with an immunesuppressed condition and tests for HIV antibodies and HHV-8 were negative. He was newly diagnosed with rheumatoid arthritis, according to the 2010 ACR-EULAR criteria. Typical findings of Kaposi¡¯s sarcoma were confirmed by biopsy. After treatment with metronomic oral etoposide 25 mg once daily for 9 months, the skin lesions had almost resolved with no serious complication. Thus, we report a rare case of Kaposi¡¯s sarcoma developing in a patient with newly diagnosed rheumatoid arthritis who showed a good response to oral etoposide.

Å°¿öµå

Ä«Æ÷½ÃÀ°Á¾, »ç¶÷¸é¿ª°áÇ̹ÙÀÌ·¯½º, »ç¶÷Ç츣Æ佺¹ÙÀÌ·¯½º 8, ¿¡ÅäÆ÷»çÀ̵å, ·ù¸¶Æ¼½º°üÀý¿°
HIV, Sarcoma, Kaposi, Herpesvirus 8, Human, Etoposide, Arthritis, Rheumatoid
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå